The global demand for Cladribine Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028. Regarding volume, the market was calculated XX Tons in 2021 and forecast to touch XX Tons by 2028 with a CAGR of XX% during 2022-2028.
Cladribine is an anti-cancer chemotherapy drug, belongs to the class of drugs called antimetabolites. It is also referred to as 2-CdA, 2-Chlorodeoxyadenosine. Cladribine is used to langerhans cell histiocytosis, treat hairy cell leukemia, chronic lymphocytic leukemia (CLL), non-hodgkin's lymphomas, acute myeloid leukemia (AML), and waldenstrom macroglobulinemia. There is a 10g pill form of cladribine. It can be administered by infusion through a vein. Cladribine is available under the different brand names: Mavenclad, Leustatin, Cladribine Novaplus, among others.
Market Dynamics
With the mounting burden of cancer patients, an aging population, and more efficient treatments, demand for cancer care is spurring. Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. The prevalence of cancer is significant and is increasing. Growing penetration of healthcare insurance worldwide is favoring chemotherapy demand, thus cladribine. Escalating approvals by FDA for a new treatment is foreseen to create new market opportunities. However, the availability of other alternatives such as fingolimod, natalizumab, alemtuzumab, and ocrelizumab is expected to hinder the global cladribine market's growth.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cladribine. The growth and trends of Cladribine Industry provide a holistic approach to this study.
Market Segmentation
This section of the cladribine market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Intravenous Injection
- Subcutaneous Injection
- Oral Tablet
By Application
- Hospital
- Cancer Center
- Other
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Cladribine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Cladribine Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cladribine market include Fresenius Medical Care, Generic Medical Partners Inc, Johnson and Johnson, Lipomed AG, Merck KGaA, Merck and Co., Strides Pharma Science Limited, Pfizer, Hikma Pharmaceuticals, Bedford Pharma, Zhejiang Hisun Pharmaceutical Co., Ltd., Viatris. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.